Emergent BioSolutions Secures $250M in Government Contract, Announces Strategic Moves Including Sale Of Baltimore Site to Boost Cash Generation and Slash Debt by $100M
Emergent BioSolutions Secures $250M in Government Contract, Announces Strategic Moves Including Sale Of Baltimore Site to Boost Cash Generation and Slash Debt by $100M
Emergent BioSolutions Inc. (NYSE:EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. This disciplined approach has enhanced Emergent's financial position, as well as enabling a customer focused, leaner and more flexible organization, and enriching its opportunities to pursue strategic initiatives.
Emergent BioSolutions Inc. (纽交所：EBS)今天强调了其在改善财务状况方面的几项最新进展，以强劲的现金生成和有意义的债务偿还为标志。根据其未来几年转型公司的运营计划，Emergent正努力执行其策略，以提高运营效率，简化成本，产生现金以增加盈利能力并减少公司总债务。这种有纪律的方法不仅增强了Emergent的财务状况，还使公司成为以客户为重点的、更精简、更灵活的组织，丰富了追求战略计划的机会。
Emergent's recent actions include:
Emergent的最新动作包括:
- Secured $250 million in U.S. government contract award modifications for four medical countermeasures
- Announced a $30 million definitive agreement to sell its Baltimore-Camden manufacturing site, which is expected to close in the third quarter of 2024, subject to the satisfaction or waiver of customary closing conditions
- Received $7 million for sale of its unimproved, empty building in Canton, Massachusetts
- As disclosed yesterday in its SEC filing, the resolution of its contract dispute with Janssen Pharmaceuticals, Inc., including the impending receipt of $50 million in the third quarter of this year
- Expected receipt of a development milestone payment as part of its Travel Health Business sale by year end
- 为四种医疗应对措施（countermeasures）获得了2.5亿美元的美国政府合同奖励改进。
- 宣布以3千万美元的价格出售其位于巴尔的摩-卡姆登（Baltimore-Camden）的制造厂，预计在2024年第三季度完成，取决于满足或放弃惯常的结束条件。
- 以700万美元的价格出售位于马萨诸塞州康顿（Canton）的未开发、空置建筑。
- 正如昨天在其SEC申报中披露的，Emergent与Janssen Pharmaceuticals，Inc.的合同争议得到了解决，包括今年第三季度即将收到5千万美元的款项。
- 预计到年底，作为其旅行健康业务出售的一部分，将收到开发里程碑付款。
"Emergent is making steady progress toward cash generation and debt repayment, which is in service to our strategic plan to stabilize our financial position and ultimately transform the organization as we continue to be a global leader in public health preparedness," said Joe Papa, president and CEO of Emergent. "We remain committed to reaching our target of more than $100 million in debt reduction this year, while continuing to deliver vital medicines to our customers and patients, creating long-term and sustainable value for shareholders and working toward strengthening our balance sheet, so that we have a healthier financial foundation to support our company's future direction."
Emergent的总裁兼首席执行官Joe Papa表示:“Emergent正稳步向现金收入和债务还款迈进，这是我们稳定财务状况和最终转型组织为全球公共卫生应对领域领导者的战略计划服务的一部分。我们仍致力于实现今年逾1亿美元的债务减少目标，同时继续向我们的客户和病患提供重要药品，为股东创造长期和可持续的价值，并努力加强我们的资产负债表，从而拥有更健康的财务基础，支持公司的未来发展方向。”
Emergent will provide more on its 2024 financial outlook, incorporating any potential expectations related to these recent events, and other relevant information when it reports its second quarter financial results in August.
Emergent将在8月份公布第二季度财报时，提供有关2024年财务前景、这些最新事件和其他相关信息的更多信息。